Codexis News

This is Codexis, and stimulate some interest on. I am John Nicols, CEO of Codexis.

Codexis, Inc. , a developer of engineered enzymes for pharmaceutical, biofuel and chemical production, today announced that John Nicols, President and CEO of Codexis, will present a company overview at the 2013 UBS Global Healthcare Conference on Monday, May 20, 2013 at 3:00 p.m. ET in New York City.

They currently have a $2.50 target price on the stock. Shares of Codexis remained flat at $2.19 during during mid-day trading trading on Wednesday.

Codexis issued its quarterly earnings data on Tuesday. The company reported EPS for the quarter, beating the Thomson Reuters consensus estimate of by $0.11, Analyst Ratings Network.com reports.

Welcome to Codexis' First Quarter Earnings Conference Call. This call is being webcast live on the Investors section of Codexis' website at codexis.com. This call is the property of Codexis and any recording, reproduction or transmission of this call without expressed written consent of Codexis is strictly prohibited.

Formerly chief executive officer of Codexis Inc., the first advanced biofuel technology company to trade on a U.S. exchange, Shaw now says it's impossible to economically turn crop waste, wood and plants like switchgrass into fuel.

Alan Shaw, the chemist and executive who led a six-year effort to turn inedible crops into fuels to displace gasoline, has renounced the industry he helped pioneer and decided the future instead lies with natural gas.

Codexis, Inc. , a developer of engineered enzymes for pharmaceutical, biofuel and chemical production, today announced it will host a live conference call and audio webcast on Tuesday, May 7, 2013 at 4:30 p.m. Eastern Time to discuss its first quarter 2013 financial results for the period ended March 31, 2013.

Brazil-based GranBio has announced plans to expand to the U.S. with an office in San Francisco and has name Vonnie Estes as the managing director.